These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 6372999)
1. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Stong RC; Youle RJ; Vallera DA Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Weil-Hillman G; Runge W; Jansen FK; Vallera DA Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376 [TBL] [Abstract][Full Text] [Related]
3. Antigenic modulation by anti-CD5 immunotoxins. Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441 [TBL] [Abstract][Full Text] [Related]
4. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720 [TBL] [Abstract][Full Text] [Related]
5. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. Youle RJ; Uckun FM; Vallera DA; Colombatti M J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613 [TBL] [Abstract][Full Text] [Related]
6. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. Uckun FM; Stong RC; Youle RJ; Vallera DA J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712 [TBL] [Abstract][Full Text] [Related]
7. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Stong RC; Uckun F; Youle RJ; Kersey JH; Vallera DA Blood; 1985 Sep; 66(3):627-35. PubMed ID: 3896347 [TBL] [Abstract][Full Text] [Related]
8. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Schmidberger H; King L; Lasky LC; Vallera DA Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258 [TBL] [Abstract][Full Text] [Related]
11. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin. Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275 [TBL] [Abstract][Full Text] [Related]
12. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Seon BK Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562 [TBL] [Abstract][Full Text] [Related]
14. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow. Quinones RR; Youle RJ; Kersey JH; Zanjani ED; Azemove SM; Soderling CC; Lebien TW; Beverley PC; Neville DM; Vallera DA J Immunol; 1984 Feb; 132(2):678-83. PubMed ID: 6606676 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Tondini C; Pap SA; Hayes DF; Elias AD; Kufe DW Cancer Res; 1990 Feb; 50(4):1170-5. PubMed ID: 2404589 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. Fishwild DM; Aberle S; Bernhard SL; Kung AH Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534 [TBL] [Abstract][Full Text] [Related]
17. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241 [TBL] [Abstract][Full Text] [Related]
18. Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation. Douay L; Gorin NC; Lopez M; Casellas P; Liance MC; Jansen FK; Voisin GA; Baillou C; Laporte JP; Najman A Cancer Res; 1985 Jan; 45(1):438-41. PubMed ID: 3880666 [TBL] [Abstract][Full Text] [Related]
19. Preclinical studies on the use of selective antibody-ricin conjugates in autologous bone marrow transplantation. Leonard JE; Taetle R; To D; Rhyner K Blood; 1985 May; 65(5):1149-57. PubMed ID: 3888307 [TBL] [Abstract][Full Text] [Related]
20. Selective T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins. Izquierdo M; Balboa MA; Figuera A; López-Botet M Clin Exp Immunol; 1988 Nov; 74(2):300-4. PubMed ID: 3265657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]